New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
10:04 EDTIBM, STO, PXD, FRX, TTEK, TOT, MXWL, AGN, WBK, RENT, SSW, ESIOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Allergan (AGN) upgraded to Buy from Neutral at SunTrust... American Express (AXP) upgraded to Positive from Neutral at Susquehanna ... Forest Labs (FRX) upgraded to Outperform from Neutral at Credit Suisse... ITT Educational (ESI) upgraded to Buy from Neutral at BofA/Merrill... Maxwell (MXWL) upgraded to Overweight from Neutral at Piper Jaffray... Pioneer Natural (PXD) upgraded to Buy from Hold at Stifel... Seaspan (SSW) upgraded to Hold from Sell at Stifel... Statoil (STO) upgraded to Buy from Hold at Deutsche Bank... Total (TOT) upgraded to Buy from Neutral at Citigroup... Rentrak (RENT) upgraded to Market Perform from Underweight at Albert Fried... IBM (IBM) upgraded to Buy from Outperform at CLSA... Tetra Tech (TTEK) upgraded to Overweight from Equal Weight at Stephens... Westpac Banking (WBK) upgraded to Neutral from Sell at Goldman.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
September 30, 2015
09:16 EDTRENTcomScore deal to improve competitive positioning, says Oppenheimer
After comScore (SCOR) agreed to buy Rentrak (RENT), Oppenheimer says that the merger "significantly increases (the company's) competitive positioning with respect to digital media analytics and measurement" The firm thinks that the deal strengthens comScore's cross-platform and video offerings. It keeps a $68 price target and Outperform rating on the shares. .
09:02 EDTRENTcomScore acquisition positive, says SunTrust
After comScore (SCOR) agreed to buy Rentrak (RENT), SunTrust says that comScore's valuation is attractive, if it is able to obtain the synergies that it's projecting from the deal. The firm notes that comScore's customers thinks the deal has "strategic merti." The firm keeps a Buy rating on comScore.
08:03 EDTIBMWest Pharmaceutical appoints Annette Favorite to Chief Human Resources Officer
Subscribe for More Information
07:54 EDTRENTRentrak downgraded to Buy from Strong Buy at Needham
Subscribe for More Information
07:14 EDTRENTcomScore, Rentrak merger makes lot of strategic sense, says William Blair
Subscribe for More Information
September 29, 2015
17:17 EDTRENTRentrak up 13% after merger agreement with subsidiary of comScore
Subscribe for More Information
16:26 EDTRENTRentrak to resume trading at 4:30 pm ET
Subscribe for More Information
16:21 EDTRENTRentrak, comScore announce stock-for-stock merger agreement
comScore (SCOR) and Rentrak (RENT) announced that the companies have entered into a definitive merger agreement under which the companies will combine in a stock-for-stock merger. Pursuant to the terms of the merger, which has been approved by the boards of both companies, Rentrak will merge into a wholly-owned subsidiary of comScore, and each share of Rentrak will be converted into the right to receive 1.15 shares of comScore. comScore shareholders are expected to own approximately 66.5% and Rentrak shareholders are expected to own approximately 33.5% of the combined company on a fully diluted basis. comScore's current CEO, Serge Matta, will lead the combined company as CEO. Magid Abraham will remain as the executive chairman of the board. Bill Livek, Rentrak's current vice chairman and CEO, will serve as the company's executive vice chairman and president. Mel Wesley will continue as CFO, and David Chemerow, Rentrak's current COO and CFO, will serve as a strategic advisor to the CEO, focused on the integration of the two companies. The combined company's board will consist of twelve directors -- eight from comScore and four from Rentrak. "This merger also recognizes the critical importance of combining digital and TV assets for next generation media measurement, which requires a higher degree of precision at both a national and local market level," remarked Serge Matta. comScore expects the transaction to be mildly dilutive to its adjusted EPS in 2016, and accretive in 2017. The combined company is expected to have total synergies of at least $20M in 2016 and at least $35M in 2017. The company also anticipates a significant portion of the synergies to be revenue related, which it expects to grow over time with an "attractive" contribution margin. The transaction is expected to be completed by early 2016.
16:16 EDTRENTRentrak to merge into wholly-owned subsidiary of comScore
16:14 EDTRENTcomScore, Rentrak to merge in stock-for-stock transaction
16:00 EDTRENTRentrak trading halted, pending news
13:32 EDTIBMIBM to create 120 positions across Ireland, Independent says
Subscribe for More Information
13:28 EDTAGNAllergan volatility at 52-week high on share price pull back
Subscribe for More Information
12:33 EDTAGNOn The Fly: Top stock stories at midday
Stocks on Wall Street were slightly higher at midday as the market seeks to break its losing streak, helped by an improvement in consumer confidence that came despite the recent market volatility. ECONOMIC EVENTS: In the U.S., consumer confidence unexpectedly rose in September. Analysts expected the consumer confidence reading to pull back to 96.8 from the prior 101.5 figure, but it actually strengthened to 103.0. The S&P/Case-Shiller 20-city composite home price index was up a seasonally adjusted 0.2% month over month in July, versus the consensus forecast for a rise of 0.1%. Stocks sold off in much of Asia last night, with China's Shanghai composite index sliding 2% while Japan's Nikkei dropped 4%, erasing year-to-date gains in the process. COMPANY NEWS: Shares of Yahoo (YHOO) advanced 3% after its board authorized the company to continue to pursue its spin-off of Aabaco Holdings, a newly formed independent registered investment company that will hold all of Yahoo's remaining holdings in Alibaba Group (BABA). MAJOR MOVERS: Among the notable gainers was Radius Health (RDUS), which rose nearly 10% after Ben Harrington of the Betaville blog stated during an appearance on Tip TV that he has heard that "something will be happening" in terms of M&A involving the company over the "next few weeks." Also higher were several recently beaten down biotech stocks that were seeing some bounceback, including Vertex Pharmaceuticals (VRTX), which gained 5%, and Biogen (BIIB), which advanced 4%. Notably, both of them, along with Amgen (AMGN), were mentioned in a note to investors by Cowen analyst Ken Cacciatore as "hypothetical" targets for Allergan (AGN). Among the noteworthy losers was OvaScience (OVAS), which dropped 38% after saying it now longer expects to meet its 2015 goal of 1,000 Augment cycles. Esperion (ESPR) also fell 38% after the company warned that the FDA could require it to undertake new studies before its ETC-1002 is approved. INDEXES: Near midday, the Dow was up 7.27, or 0.05%, to 16,009.16, the Nasdaq was up 7.38, or 0.16%, to 4,551.35, and the S&P 500 was up 4.56, or 0.24%, to 1,886.33.
10:07 EDTRENTRentrak to host investor day
Investor Day to be held in New York on October 1 at 12:30 pm. Webcast Link
10:00 EDTAGNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:57 EDTAGNCowen lists Vertex, Biogen and Amgen as hypothetical Allergan targets
Cowen analyst Ken Cacciatore noted that the price agreed for Allergan's (AGN) generic divestiture to Teva (TEVA) is fixed and that the cash value from this deal has not depreciated in any way while the corresponding valuations of potential targets have corrected, increasing the potential value creation available for Allergan as it decides how to deploy its capital. To illustrate the value creation that Allergan's capital deployment could generate, Cacciatore estimates the type of accretion potential that might be seen if the company were to buy Vertex with an acquisition price of $36.5B, if it were to acquire Biogen (BIIB) at a price of $91B or if it were to purchase Amgen (AMGN) with an acquisition price of $140B. Although the market correction has lowered Allergan's stock, the decline could be viewed as a near-term positive, given that a key component of its strategy and business model is to seek to aggressively deploy its capital, Cacciatore argues in a note to investors. The analyst keeps an Outperform rating and $400 price target on Allergan shares.
08:18 EDTAGNAllergan initiated with a Buy at Nomura
Subscribe for More Information
08:03 EDTAGNAllergan price target lowered to $311 from $357 at Leerink
Subscribe for More Information
07:09 EDTAGNAllergan selloff brings 'compelling' buying opportunity, says JPMorgan
Subscribe for More Information
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use